{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    5,
    6,
    7,
    8,
    14,
    15,
    18,
    21,
    22,
    25
  ],
  "modelUsed": "claude-opus-4-5",
  "confidence": 1.0,
  "amendmentDetails": {
    "studyAmendmentImpacts": [
      {
        "id": "impact_1",
        "amendmentId": "amend_3",
        "affectedSection": "Protocol Title",
        "impactLevel": "Administrative",
        "instanceType": "StudyAmendmentImpact",
        "description": "Revised title to change fibrosis stages from 'F2 Through F4' to 'F1 Through F4'"
      },
      {
        "id": "impact_2",
        "amendmentId": "amend_3",
        "affectedSection": "Section 1.1 Synopsis",
        "impactLevel": "Major",
        "instanceType": "StudyAmendmentImpact",
        "description": "Multiple clarifications including fibrosis stage definitions, NASH indication terminology, dosing schedule clarification, and screening period requirements"
      },
      {
        "id": "impact_3",
        "amendmentId": "amend_3",
        "affectedSection": "Section 5.1 Inclusion Criteria",
        "impactLevel": "Major",
        "instanceType": "StudyAmendmentImpact",
        "description": "Removed Inclusion Criterion #4 (FAST Score), revised Criterion #6 to lower NAS requirement from ≥4 to ≥3 and fibrosis stage from F2 to F1"
      },
      {
        "id": "impact_4",
        "amendmentId": "amend_3",
        "affectedSection": "Section 5.2 Exclusion Criteria",
        "impactLevel": "Major",
        "instanceType": "StudyAmendmentImpact",
        "description": "Revised Exclusion Criteria #1, #2, #6a, #7, #17, #21, #25, #26 including removal of SARS-CoV-2 infection criterion"
      },
      {
        "id": "impact_5",
        "amendmentId": "amend_3",
        "affectedSection": "Section 5.4 Screening",
        "impactLevel": "Minor",
        "instanceType": "StudyAmendmentImpact",
        "description": "Added statements related to screening period extension, SARS-CoV-2 testing requirements, and rescreening allowances"
      },
      {
        "id": "impact_6",
        "amendmentId": "amend_3",
        "affectedSection": "Section 4.1 Overall Design",
        "impactLevel": "Minor",
        "instanceType": "StudyAmendmentImpact",
        "description": "Added cap of four participants with F1 fibrosis enrollment"
      },
      {
        "id": "impact_7",
        "amendmentId": "amend_3",
        "affectedSection": "Schedule of Activities Tables 1, 2, 3",
        "impactLevel": "Minor",
        "instanceType": "StudyAmendmentImpact",
        "description": "Restructured tables, added new Table 2 for Visit 4a and 4a2, revised footnotes and column structure"
      },
      {
        "id": "impact_8",
        "amendmentId": "amend_3",
        "affectedSection": "Section 10.3.1 Definition of Adverse Event",
        "impactLevel": "Minor",
        "instanceType": "StudyAmendmentImpact",
        "description": "Added definition statement for adverse events and new subsection for pretreatment-emergent adverse events"
      },
      {
        "id": "impact_9",
        "amendmentId": "amend_3",
        "affectedSection": "Section 10.3.4.4 Action Taken",
        "impactLevel": "Administrative",
        "instanceType": "StudyAmendmentImpact",
        "description": "Removed 'dose increased' and 'dose reduced' from Action Taken options"
      },
      {
        "id": "impact_10",
        "amendmentId": "amend_3",
        "affectedSection": "Section 5.4.1 Screen Failures",
        "impactLevel": "Minor",
        "instanceType": "StudyAmendmentImpact",
        "description": "Removed 4-week waiting period requirement for rescreening"
      },
      {
        "id": "impact_11",
        "amendmentId": "amend_3",
        "affectedSection": "Section 8 Study Assessments and Procedures",
        "impactLevel": "Minor",
        "instanceType": "StudyAmendmentImpact",
        "description": "Added instruction for immunogenicity sample collection when worsening of disease is reported as AE"
      }
    ],
    "studyAmendmentReasons": [
      {
        "id": "reason_1",
        "amendmentId": "amend_3",
        "reasonText": "Revise inclusion and exclusion criteria to improve study feasibility",
        "category": "Operational",
        "isPrimary": true,
        "instanceType": "StudyAmendmentReason"
      },
      {
        "id": "reason_2",
        "amendmentId": "amend_3",
        "reasonText": "Clarify the screening period eligibility and extension of its duration",
        "category": "Operational",
        "isPrimary": true,
        "instanceType": "StudyAmendmentReason"
      },
      {
        "id": "reason_3",
        "amendmentId": "amend_3",
        "reasonText": "Clarify the acceptable conditions for including SARS-CoV-2-infected participants into the study and to allow adequate time for recovery of symptoms before screening",
        "category": "Safety",
        "isPrimary": true,
        "instanceType": "StudyAmendmentReason"
      },
      {
        "id": "reason_4",
        "amendmentId": "amend_3",
        "reasonText": "Correction of protocol title",
        "category": "Administrative",
        "isPrimary": false,
        "instanceType": "StudyAmendmentReason"
      },
      {
        "id": "reason_5",
        "amendmentId": "amend_3",
        "reasonText": "Clarification of terminology and procedures throughout protocol",
        "category": "Administrative",
        "isPrimary": false,
        "instanceType": "StudyAmendmentReason"
      },
      {
        "id": "reason_6",
        "amendmentId": "amend_3",
        "reasonText": "To have a wider and diverse range of participants from all fibrosis stages (F1 through F4cc) enrolled in the study",
        "category": "Scientific",
        "isPrimary": false,
        "instanceType": "StudyAmendmentReason"
      },
      {
        "id": "reason_7",
        "amendmentId": "amend_3",
        "reasonText": "To improve study feasibility by expanding the study inclusion parameters while maintaining a population that is optimal for assessing the anti-inflammatory/anti-fibrogenic mechanism of this drug",
        "category": "Scientific",
        "isPrimary": false,
        "instanceType": "StudyAmendmentReason"
      },
      {
        "id": "reason_8",
        "amendmentId": "amend_3",
        "reasonText": "NAS ≥4 to NAS ≥3 to reduce screen failures on NAS subscores due to nonreliability of the ballooning score",
        "category": "Operational",
        "isPrimary": false,
        "instanceType": "StudyAmendmentReason"
      },
      {
        "id": "reason_9",
        "amendmentId": "amend_3",
        "reasonText": "To improve study feasibility, recognizing the study population to be enrolled (HbA1c requirement change)",
        "category": "Operational",
        "isPrimary": false,
        "instanceType": "StudyAmendmentReason"
      },
      {
        "id": "reason_10",
        "amendmentId": "amend_3",
        "reasonText": "To correct the list of possible actions that can be taken in response to an adverse event, given that a single dose of ontamalimab (75 mg) is available for use in this study",
        "category": "Administrative",
        "isPrimary": false,
        "instanceType": "StudyAmendmentReason"
      },
      {
        "id": "reason_11",
        "amendmentId": "amend_3",
        "reasonText": "To allow participants to rescreen on a case-by-case basis after discussion with the investigator",
        "category": "Operational",
        "isPrimary": false,
        "instanceType": "StudyAmendmentReason"
      },
      {
        "id": "reason_12",
        "amendmentId": "amend_3",
        "reasonText": "To clarify the instructions for collection of samples for immunogenicity in case of worsening of a disease being reported as an AE",
        "category": "Scientific",
        "isPrimary": false,
        "instanceType": "StudyAmendmentReason"
      }
    ],
    "studyChanges": [
      {
        "id": "change_1",
        "amendmentId": "amend_3",
        "changeType": "Modification",
        "instanceType": "StudyChange",
        "sectionNumber": "Title",
        "beforeText": "A Multicenter, Single-arm, Open-label, Phase 1b Study to Explore the Mechanism of Action and Evaluate the Safety of Ontamalimab in Participants With Nonalcoholic Steatohepatitis With Fibrosis Stages 2 Through 4",
        "afterText": "A Multicenter, Single-arm, Open-label, Phase 1b Study to Explore the Mechanism of Action and Evaluate the Safety of Ontamalimab in Participants With Nonalcoholic Steatohepatitis With Fibrosis Stage 1 Through 4",
        "summary": "Changed fibrosis stage range from F2-F4 to F1-F4 in protocol title"
      },
      {
        "id": "change_2",
        "amendmentId": "amend_3",
        "changeType": "Clarification",
        "instanceType": "StudyChange",
        "sectionNumber": "1.1",
        "beforeText": "Ontamalimab will be administered at Day 1 and Q4W thereafter for up to 24 weeks (last dose at Week 20)",
        "afterText": "Ontamalimab will be administered subcutaneously (SC) every 4 weeks (Q4W) starting on Day 1 and the last dose is administered at Week 20 (total treatment period is 24 weeks)",
        "summary": "Clarified dosing schedule and administration route"
      },
      {
        "id": "change_3",
        "amendmentId": "amend_3",
        "changeType": "Addition",
        "instanceType": "StudyChange",
        "sectionNumber": "1.1/4.1",
        "afterText": "Not more than four participants with F1 fibrosis will be enrolled in this study",
        "summary": "Added cap on F1 fibrosis participant enrollment"
      },
      {
        "id": "change_4",
        "amendmentId": "amend_3",
        "changeType": "Deletion",
        "instanceType": "StudyChange",
        "sectionNumber": "5.1",
        "beforeText": "Inclusion Criterion #4 (FibroScan-aspartate aminotransferase [FAST] Score as eligibility criterion for liver biopsy)",
        "summary": "Removed FAST Score as eligibility criterion for liver biopsy"
      },
      {
        "id": "change_5",
        "amendmentId": "amend_3",
        "changeType": "Modification",
        "instanceType": "StudyChange",
        "sectionNumber": "5.1",
        "beforeText": "The participant has a diagnosis of NASH confirmed via biopsy (NAS ≥4 with at least 1 point each in steatosis, ballooning, and lobular inflammation) and liver fibrosis stage F2, F3, or F4cc according to NASH CRN, and established according to appropriate guidelines",
        "afterText": "The participant has indication of NASH via biopsy (NAS ≥3 with at least 1 point in lobular inflammation) and liver fibrosis stage F1 through F4cc according to NASH CRN",
        "summary": "Lowered NAS requirement from ≥4 to ≥3, removed steatosis and ballooning requirements, expanded fibrosis stages to include F1"
      },
      {
        "id": "change_6",
        "amendmentId": "amend_3",
        "changeType": "Modification",
        "instanceType": "StudyChange",
        "sectionNumber": "5.1",
        "beforeText": "Enrollment of F2 and F3 participants at a 1:1 ratio will not be required",
        "afterText": "Enrollment of F1, F2 and F3 participants at a 1:1:1 ratio will not be required",
        "summary": "Updated enrollment ratio statement to include F1 participants"
      },
      {
        "id": "change_7",
        "amendmentId": "amend_3",
        "changeType": "Modification",
        "instanceType": "StudyChange",
        "sectionNumber": "5.2",
        "beforeText": "HbA1c requirement of ≥8% at Week -8 (SV1)",
        "afterText": "HbA1c requirement of ≥9% at Week -8 (SV1)",
        "summary": "Increased HbA1c exclusion threshold from ≥8% to ≥9%"
      },
      {
        "id": "change_8",
        "amendmentId": "amend_3",
        "changeType": "Deletion",
        "instanceType": "StudyChange",
        "sectionNumber": "5.2",
        "beforeText": "Exclusion Criterion #17: severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection",
        "summary": "Removed SARS-CoV-2 infection as exclusion criterion"
      },
      {
        "id": "change_9",
        "amendmentId": "amend_3",
        "changeType": "Modification",
        "instanceType": "StudyChange",
        "sectionNumber": "5.2",
        "beforeText": "The following laboratory findings are exclusionary for all participants if found during either screening visit (Week -8 or Week -6)",
        "afterText": "The following laboratory findings are exclusionary for all participants if found during screening visits (Week -8 [SV1], Week -6 [SV2] or at Day -4 visit [Visit 4a2])",
        "summary": "Added Day -4 visit to screening laboratory exclusion timeframe"
      },
      {
        "id": "change_10",
        "amendmentId": "amend_3",
        "changeType": "Addition",
        "instanceType": "StudyChange",
        "sectionNumber": "5.2",
        "afterText": "Treatment with leukocyte apheresis or selective lymphocyte, monocyte, or granulocyte apheresis or plasma exchange 30 days before baseline (Day 1)",
        "summary": "Added additional exclusion criterion #7 regarding apheresis treatments"
      },
      {
        "id": "change_11",
        "amendmentId": "amend_3",
        "changeType": "Modification",
        "instanceType": "StudyChange",
        "sectionNumber": "5.4.1",
        "beforeText": "An individual who has been designated a screen failure may be rescreened once, except for participants who fail the histological evaluation of the liver biopsy.",
        "afterText": "An individual who has been designated a screen failure may be rescreened once",
        "summary": "Removed exception for histological evaluation failures from rescreening allowance"
      },
      {
        "id": "change_12",
        "amendmentId": "amend_3",
        "changeType": "Deletion",
        "instanceType": "StudyChange",
        "sectionNumber": "5.4.1",
        "beforeText": "after 4 weeks of last sample taken at the initial screening",
        "summary": "Removed 4-week waiting period requirement for rescreening"
      },
      {
        "id": "change_13",
        "amendmentId": "amend_3",
        "changeType": "Addition",
        "instanceType": "StudyChange",
        "sectionNumber": "5.4",
        "afterText": "Maximum allowed time between historical liver biopsy and first dose of study drug is 34 weeks for any participant, except for the participants who test positive for SARS-CoV-2 at screening",
        "summary": "Added maximum time allowance for historical liver biopsy"
      },
      {
        "id": "change_14",
        "amendmentId": "amend_3",
        "changeType": "Addition",
        "instanceType": "StudyChange",
        "sectionNumber": "5.4",
        "afterText": "In case of positive test for SARS-CoV-2 infection, screening may be paused for an additional 2 weeks (ie, screening period of up to 12 weeks)",
        "summary": "Added screening extension allowance for SARS-CoV-2 positive participants"
      },
      {
        "id": "change_15",
        "amendmentId": "amend_3",
        "changeType": "Addition",
        "instanceType": "StudyChange",
        "sectionNumber": "5.4",
        "afterText": "The screening period can be extended by 2 weeks for any reason (including but not limited to a repeat test requirement for select and predefined measurements) on a case-by-case basis with the sponsor's approval",
        "summary": "Added general screening extension allowance with sponsor approval"
      },
      {
        "id": "change_16",
        "amendmentId": "amend_3",
        "changeType": "Modification",
        "instanceType": "StudyChange",
        "sectionNumber": "9.3",
        "beforeText": "During the screening period, Pro-C3, ELF, and other exploratory markers will be measured at 3 visits (including Day 1 predose) to determine intra-participant variability.",
        "afterText": "Pro-C3, ELF, and other exploratory markers will be measured at 2 screening visits (SV1 and SV2) and Day 1 [D1] predose measurement during treatment period to determine intra-participant variability.",
        "summary": "Clarified biomarker measurement timing across screening and treatment periods"
      },
      {
        "id": "change_17",
        "amendmentId": "amend_3",
        "changeType": "Deletion",
        "instanceType": "StudyChange",
        "sectionNumber": "10.3.4.4",
        "beforeText": "dose increased, dose reduced",
        "summary": "Removed dose modification options from Action Taken list since single dose is used"
      },
      {
        "id": "change_18",
        "amendmentId": "amend_3",
        "changeType": "Addition",
        "instanceType": "StudyChange",
        "sectionNumber": "8",
        "afterText": "and samples for immunogenicity should be collected when worsening of a disease is reported as an AE",
        "summary": "Added instruction for immunogenicity sample collection during disease worsening AEs"
      },
      {
        "id": "change_19",
        "amendmentId": "amend_3",
        "changeType": "Addition",
        "instanceType": "StudyChange",
        "sectionNumber": "10.3.1",
        "afterText": "an adverse event (AE) is defined as any untoward medical occurrence in a clinical investigation participant who has signed informed consent to participate in a study; it does not necessarily have to have a causal relationship with the treatment",
        "summary": "Added explicit definition of adverse event"
      },
      {
        "id": "change_20",
        "amendmentId": "amend_3",
        "changeType": "Addition",
        "instanceType": "StudyChange",
        "sectionNumber": "10.3.4.9",
        "afterText": "Pretreatment-emergent Adverse Events subsection",
        "summary": "Added new subsection defining pretreatment-emergent adverse events"
      },
      {
        "id": "change_21",
        "amendmentId": "amend_3",
        "changeType": "Modification",
        "instanceType": "StudyChange",
        "sectionNumber": "1.3.1",
        "beforeText": "Table 1. Schedule of Activities: Screening Period",
        "afterText": "Table 1. Schedule of Activities: Screening Period (Visit 1 and 2)",
        "summary": "Revised table title to specify visits covered"
      },
      {
        "id": "change_22",
        "amendmentId": "amend_3",
        "changeType": "Addition",
        "instanceType": "StudyChange",
        "sectionNumber": "1.3.1",
        "afterText": "Table 2. Schedule of Activities: Screening Period (Visit 4a and 4a2)",
        "summary": "Added new table for Visit 4a and 4a2 screening activities"
      },
      {
        "id": "change_23",
        "amendmentId": "amend_3",
        "changeType": "Deletion",
        "instanceType": "StudyChange",
        "sectionNumber": "1.3.2",
        "beforeText": "Columns for Visit 4a and Visit 4a2 in Table Schedule of Activities: Treatment Period",
        "summary": "Removed Visit 4a and 4a2 columns from treatment period table (moved to new screening table)"
      }
    ],
    "summary": {
      "impactCount": 11,
      "reasonCount": 12,
      "changeCount": 23
    }
  }
}